SARS vaccine development.

Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main concern. The spike (S) protein of SARS-CoV is the major inducer of neutralizing antibodies, and the receptor-binding domain (RBD) in the S1 subunit of S protein contains multiple conformational neutralizing epitopes. This suggests that recombinant proteins containing RBD and vectors encoding the RBD sequence can be used to develop safe and effective SARS vaccines.

• Publication year

  2005

• Venue

  Emerging Infectious Diseases

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.3201/1107.050219PMID 16022774PMCID PMC3371787
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amino Acids 1055 to 1192 in the S2 Region of Severe Acute Respiratory Syndrome Coronavirus S Protein Induce Neutralizing Antibodies: Implications for the Development of Vaccines and Antiviral Agents

  2005cited by this paper
• Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines

  2005cited by this paper
• Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses.

  2005influential reference
• Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Contains Multiple Conformation-Dependent Epitopes that Induce Highly Potent Neutralizing Antibodies

  2005cited by this paper
• B-Cell Responses in Patients Who Have Recovered from Severe Acute Respiratory Syndrome Target a Dominant Site in the S2 Domain of the Surface Spike Glycoprotein

  2005cited by this paper
• Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV)

  2005cited by this paper
• Identification of Two Neutralizing Regions on the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Produced from the Mammalian Expression System

  2005cited by this paper
• Molecular and Biological Characterization of Human Monoclonal Antibodies Binding to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome Coronavirus

  2005cited by this paper
• Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding Region

  2005cited by this paper
• Identification of Immunodominant Sites on the Spike Protein of Severe Acute Respiratory Syndrome (SARS) Coronavirus: Implication for Developing SARS Diagnostics and Vaccines

  2004cited by this paper
• What’s new in the renin-angiotensin system?

  2004influential reference
• A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

  2004cited by this paper
• pH-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus Is Mediated by the Spike Glycoprotein and Enhanced by Dendritic Cell Transfer through DC-SIGN

  2004cited by this paper
• Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China.

  2004cited by this paper
• Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice

  2004cited by this paper
• Medicine. Caution urged on SARS vaccines.

  2004cited by this paper
• Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors

  2004cited by this paper
• Immunogenicity of SARS inactivated vaccine in BALB/c mice

  2004cited by this paper
• CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus.

  2004cited by this paper
• Crystal Structure of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Fusion Core*

  2004cited by this paper
• Immunization with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe Acute Respiratory Syndrome Is Associated with Enhanced Hepatitis in Ferrets

  2004cited by this paper
• Structural Characterization of the SARS-Coronavirus Spike S Fusion Protein Core

  2004cited by this paper
• Caution Urged on SARS Vaccines

  2004cited by this paper
• Molecular Evolution of the SARS Coronavirus During the Course of the SARS Epidemic in China

  2004cited by this paper
• Severe acute respiratory syndrome

  2004cited by this paper
• Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.

  2004cited by this paper
• Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS

  2004cited by this paper
• Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine

  2004cited by this paper
• Molecular epidemiology of the novel coronavirus that causes severe acute respiratory syndrome

  2004cited by this paper
• A 193-Amino Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2*

  2004cited by this paper
• Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry

  2004cited by this paper
• Glycan arrays lead to the discovery of autoimmunogenic activity of SARS-CoV

  2004cited by this paper
• A model of the ACE2 structure and function as a SARS-CoV receptor

  2003influential reference
• The SARS-CoV S glycoprotein: expression and functional characterization

  2003cited by this paper
• SARS-associated coronavirus.

  2003cited by this paper
• The Severe Acute Respiratory Syndrome

  2003influential reference
• Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS)

  2003cited by this paper
• Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

  2003cited by this paper
• Unique and Conserved Features of Genome and Proteome of SARS-coronavirus, an Early Split-off From the Coronavirus Group 2 Lineage

  2003cited by this paper
• Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China

  2003cited by this paper
• The Secret Life of ACE2 as a Receptor for the SARS Virus

  2003cited by this paper
• Identification of antigenic sites mediating antibody-dependent enhancement of feline infectious peritonitis virus infectivity.

  1993cited by this paper
• Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41 [published erratum appears in J Exp Med 1992 Feb 1;175(2):621]

  1991cited by this paper
• Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41.

  1991cited by this paper

• Efficacy of Immunostimulatory Adjuvants and Nano‐Adjuvants in Current SARS‐CoV‐2 Vaccines: A Comprehensive Review

  2025cites this paper
• Towards a Comprehensive Definition of Pandemics and Strategies for Prevention: A Historical Review and Future Perspectives

  2024cites this paper
• Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines

  2023cites this paper
• B lymphocytes in COVID-19: a tale of harmony and discordance

  2023cites this paper
• Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines

  2023cites this paper
• Application of Traditional Vaccine Development Strategies to SARS-CoV-2

  2023influential citation
• A global survey in the developmental landscape of possible vaccination strategies for COVID-19

  2022cites this paper
• Recent developments in SARS‐CoV‐2 vaccines: A systematic review of the current studies

  2022cites this paper
• Recent advances in the vaccine development for the prophylaxis of SARS Covid-19

  2022cites this paper
• A conserved subunit vaccine designed against SARS-CoV-2 variants showed evidence in neutralizing the virus

  2022cites this paper
• Immunogenicity of Inactivated SARS-CoV-2 Vaccines in Patients With Rheumatoid Arthritis: A Case Series

  2022cites this paper
• Recent advances in the vaccine development for the prophylaxis of SARS Covid-19 International Immunopharmacology

  2022cites this paper
• Recent advances in the vaccine development for the prophylaxis of SARS Covid-19 International Immunopharmacology

  2022cites this paper
• Application of Traditional Vaccine Development Strategies to SARS-CoV-2

  2022cites this paper
• Development of variant‐proof severe acute respiratory syndrome coronavirus 2, pan‐sarbecovirus, and pan‐β‐coronavirus vaccines

  2022cites this paper
• Virus-Like Particles of SARS-CoV-2 as Virus Surrogates: Morphology, Immunogenicity, and Internalization in Neuronal Cells

  2022cites this paper
• Antiviral effects of azithromycin: A narrative review

  2022cites this paper
• Recent trends in next generation immunoinformatics harnessed for universal coronavirus vaccine design

  2022cites this paper
• Design and Immunological Properties of the Novel Subunit Virus-like Vaccine against SARS-CoV-2

  2022cites this paper
• Recent advances in the vaccine development for the prophylaxis of SARS Covid-19 International Immunopharmacology

  2022cites this paper
• A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines

  2022cites this paper
• Comparative highlights on MERS-CoV, SARS-CoV-1, SARS-CoV-2, and NEO-CoV

  2022cites this paper
• Moving beyond Titers

  2022cites this paper
• A Borderless Solution Is Needed for A Borderless Complexity, Like COVID-19, the Universal Invader.

  2021cites this paper
• A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters

  2021cites this paper
• COVID-19: can we treat the mother without harming her baby?

  2021cites this paper
• The COVID-19 Vaccine Landscape.

  2021cites this paper
• A comprehensive insight on the COVID-19 vaccine candidates

  2021cites this paper
• Origin, Pathogenesis, Diagnosis and Treatment Options for SARS-CoV-2: A Review

  2021cites this paper
• Altered N-/O-Glycosylation Sites On The Receptor-Binding Domain (RBD) in COVID-19 Are Related To Coronavirus Infection And Pathogenesis.

  2021cites this paper
• An Overview of Spike Surface Glycoprotein in Severe Acute Respiratory Syndrome–Coronavirus

  2021cites this paper
• Transmission and Protection against Reinfection in the Ferret Model with the SARS-CoV-2 USA-WA1/2020 Reference Isolate

  2021cites this paper
• Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic

  2021cites this paper
• Energetic photons applied to COVID-19 Coronavirus S2 subunit of spike glycoprotein for host cell entry inhabitation: An alternative approach for conventional vaccination

  2021cites this paper
• Alternative strategies in cardiac preclinical research and new clinical trial formats

  2021cites this paper
• COVID-19 Vaccination: From Interesting Agent to the Patient

  2021cites this paper
• Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination

  2021cites this paper
• The development of COVID-19 vaccines in the United States: Why and how so fast?

  2021cites this paper
• An overview of some potential immunotherapeutic options against COVID-19

  2021cites this paper
• Determination of Spectrum of Symptoms Observed Followed by Administration of 1st and 2nd Doses of COVISHIELD™ Vaccine in Datta Meghe Institute of Medical Sciences (Deemed to be University) – A Study Protocol

  2021cites this paper
• Identification of a Novel Neutralizing Epitope on the N-Terminal Domain of the Human Coronavirus 229E Spike Protein

  2021cites this paper
• Features of Pathobiology and Clinical Translation of Approved Treatments for Coronavirus Disease 2019

  2021cites this paper
• SARS-CoV-2: Insights into its structural intricacies and functional aspects for drug and vaccine development

  2021cites this paper
• Exploration of antigenic determinants in spike glycoprotein of SARS-CoV2 and identification of five salient potential epitopes

  2021cites this paper
• Immune response scenario and vaccine development for SARS-CoV-2 infection

  2021cites this paper
• The value of infectious disease modeling and trend assessment: a public health perspective

  2021cites this paper
• Vaccine design and delivery approaches for COVID-19

  2021cites this paper
• A Comparative Study Between Nasopharyngeal/Oropharyngeal, Faecal and Saliva Viral Shedding In Ghanaian COVID-19 Patients attending KATH from October-December, 2020

  2021cites this paper
• SARS-CoV 2 spike protein S1 subunit as an ideal target for stable vaccines: A bioinformatic study

  2021cites this paper
• Evaluation of a Pseudovirus Neutralization Assay for SARS-CoV-2 and Correlation with Live Virus-Based Micro Neutralization Assay

  2021cites this paper
• Combating Human Viral Diseases: Will Plant-Based Vaccines Be the Answer?

  2021cites this paper
• Various theranostics and immunization strategies based on nanotechnology against Covid-19 pandemic: An interdisciplinary view

  2021cites this paper
• Nano‐therapeutic strategies to target coronavirus

  2021cites this paper
• Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Based Novel Epitopes Induce Potent Immune Responses in vivo and Inhibit Viral Replication in vitro

  2021cites this paper
• ¿Quo Vadis COVID-19?

  2021cites this paper
• Saffron: A potential drug-supplement for severe acute respiratory syndrome coronavirus (COVID) management

  2021cites this paper
• Coronavirus Pseudotypes for All Circulating Human Coronaviruses for Quantification of Cross-Neutralizing Antibody Responses

  2021cites this paper
• An easy method for developing fusion enabled SARS-CoV2 virus fusion mimic (SCFM), bypassing the need of Bio Safety Level (BSL) facility

  2021cites this paper
• COVID-19 vaccine: where are we now and where should we go?

  2021cites this paper
• Nanotherapeutics for treating coronavirus diseases

  2021cites this paper
• Designing a next generation multi-epitope based peptide vaccine candidate against SARS-CoV-2 using computational approaches

  2021cites this paper
• Общая характеристика адъювантов и механизм их действия (часть 2)

  2021cites this paper
• SARS-CoV-2 Spike Protein Extrapolation for COVID Diagnosis and Vaccine Development

  2021cites this paper
• SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid Resolution

  2020cites this paper
• Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

  2020cites this paper
• COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics

  2020cites this paper
• The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines

  2020cites this paper
• An overview of key potential therapeutic strategies for combat in the COVID-19 battle

  2020cites this paper
• Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses

  2020cites this paper
• The 2019 coronavirus: Learning curves, lessons, and the weakest link

  2020cites this paper
• Targeting severe acute respiratory syndrome-coronavirus (SARS-CoV-1) with structurally diverse inhibitors: a comprehensive review

  2020cites this paper
• Emerging novel coronavirus (2019-nCoV)—current scenario, evolutionary perspective based on genome analysis and recent developments

  2020cites this paper
• Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV

  2020cites this paper
• DBCOVP: A database of coronavirus virulent glycoproteins

  2020cites this paper
• Designing an efficient multi-epitope vaccine displaying interactions with diverse HLA molecules for an efficient humoral and cellular immune response to prevent COVID-19 infection

  2020cites this paper
• Insights of Novel Coronavirus (SARS-CoV-2) disease outbreak, management and treatment

  2020cites this paper
• Disclosure to vaccine trial subjects of specific risk of COVID-19 vaccines worsening clinical disease in informed consents

  2020cites this paper
• COVID-19 Vaccine Development, Trials and Tribulations

  2020cites this paper
• Transmission and protection against re-infection in the ferret model with the SARS-CoV-2 USA-WA1/2020 reference isolate

  2020cites this paper
• Vaccine Development Against SARS-CoV-2: From Virology to Vaccine Clinical Trials

  2020cites this paper
• The multi-epitope vaccine prediction to combat Pandemic SARS-CoV-2, an immunoinformatic approach

  2020cites this paper
• Severe acute respiratory syndrome‐coronavirus‐2 spike (S) protein based vaccine candidates: State of the art and future prospects

  2020cites this paper
• Challenges and prospects of COVID‐19 vaccine development based on the progress made in SARS and MERS vaccine development

  2020cites this paper
• Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19

  2020cites this paper
• Lessons Learned from SARS-CoV and MERS-CoV: Preparation for SARS-CoV-2 induced COVID-19

  2020cites this paper
• Protein Footprinting, Conformational Dynamics, and Core Interface-Adjacent Neutralization “Hotspots” in the SARS-CoV-2 Spike Protein Receptor Binding Domain/Human ACE2 Interaction

  2020cites this paper
• Animal and human RNA viruses: genetic variability and ability to overcome vaccines

  2020cites this paper
• The Potential Vaccine Component for COVID-19: A Comprehensive Review of Global Vaccine Development Efforts

  2020cites this paper
• The Strengths, Weaknesses, Opportunities and Threats (SWOT) Analysis of the Severe Acute Respiratory Syndrome Coronavirus 2 of COVID-19

  2020cites this paper
• The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens

  2020cites this paper
• CoronaVR: A Computational Resource and Analysis of Epitopes and Therapeutics for Severe Acute Respiratory Syndrome Coronavirus-2

  2020influential citation
• An alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates

  2020cites this paper
• The Global Emergency of Novel Coronavirus (SARS-CoV-2): An Update of the Current Status and Forecasting

  2020cites this paper
• COVID-19: A Review on Diagnosis, Treatment, and Prophylaxis

  2020cites this paper
• The effect of nationwide quarantine on anxiety levels during the COVID‐19 outbreak in China

  2020cites this paper
• SARS‐CoV‐2 S1 is superior to the RBD as a COVID‐19 subunit vaccine antigen

  2020cites this paper
• Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine

  2020cites this paper
• What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist

  2020cites this paper
• Peptides to combat viral infectious diseases

  2020cites this paper
• Immune-mediated approaches against COVID-19

  2020cites this paper